What is GHRP-2?
GHRP-2 is a synthetic ghrelin-pathway agonist studied for growth-hormone release and eating behavior. Those effects have different practical implications.
Biological role or research focus
Growth-hormone release.
Hormone-release measurements do not establish long-term muscle gain or a favorable benefit-risk balance.
Role reference: Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. ↗
Names you may encounter
GHRP 2 · GHRP2 · pralmorelin
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Growth-hormone secretagogue
- Main research area
- Hormone release and appetite
- Evidence featured
- Small human physiology study
- Source check
- October 4, 2026
Source: Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. ↗
Quick answers
- Is GHRP-2 FDA approved?
- No. No FDA-approved drug contains GHRP-2. FDA lists it in 503A category 3: nominated for compounding without enough supporting information. Source ↗
- Is GHRP-2 safe?
- GHRP-2 is a growth-hormone secretagogue not approved in the U.S. Human studies are small and short, and FDA cites serious adverse events reported with its use, though causality is unproven. Human safety data: very limited. The Risks & interactions section below lists what is known. Read the risks ↓
- Is GHRP-2 banned in sport?
- Yes. The 2026 World Anti-Doping Agency (WADA) Prohibited List names it (S2.2.4 Growth hormone releasing factors). Source ↗
- Has the FDA taken action over GHRP-2?
- Yes. Our records list 1 FDA action naming it, most recently on April 1, 2020: FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing GHRP-2 among bulk substances that are not eligible for 503A compounding exemptions. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Appetite and hormone experiment (2005) | Small human physiology study | Seven lean healthy men. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Small human physiology study · 2005
Appetite and hormone experiment
Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men.
- Population / model
- Seven lean healthy men.
- Study design
- GHRP-2 and saline infusion conditions followed by a buffet meal.
- Main finding
- Participants ate approximately 36% more during GHRP-2 exposure, and growth-hormone release increased. Every participant ate more in the active condition.
- Limits & context
- An acute meal response in seven men is not evidence for sustained body-composition improvement. Increased appetite may be relevant when interpreting weight-loss marketing.
Source: Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming GHRP-2 as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Ipamorelin, the first selective growth hormone secretagogue. ↗
European journal of endocrinology · 1998 Nov · Journal Article
Growth hormone-releasing peptides. ↗
European journal of endocrinology · 1997 May · Journal Article, Research Support, Non-U.S. Gov't, Review
Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. ↗
Drug testing and analysis · 2015 Oct · Journal Article, Research Support, Non-U.S. Gov't, Validation Study
Adult growth hormone deficiency: current concepts. ↗
Neurologia medico-chirurgica · 2014 · Journal Article, Research Support, Non-U.S. Gov't, Review
Read available full text ↗
Risks & interactions
GHRP-2 is a growth-hormone secretagogue not approved in the U.S. Human studies are small and short, and FDA cites serious adverse events reported with its use, though causality is unproven.
Evidence comes from small, short physiology and diagnostic-test studies showing rises in growth hormone, ACTH and appetite. These cannot show the safety of repeated use.
Unassessed: little human safety data
Take extra care with: Diabetes or blood-sugar medicines
It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Interactions
- Diabetes: FDA notes reports of higher insulin needs to control blood glucose
Serious risks
- FDA: reports of increased insulin requirement, deaths of critically ill study subjects, infection and pancreatitis (causality not established)
- FDA: possible immune reactions (immunogenicity) and impurity problems with injectable and nasal compounded forms
Side effects reported in studies
- increased appetite
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks (category 2) ↗ · GHRP-2 increases food intake in healthy men (2005) ↗ · GHRP-2 test for hypothalamic-pituitary disorder (2022) ↗ · Safety and efficacy of growth hormone secretagogues (review, 2018) ↗
Safety evidence & remaining uncertainty
The seven-person experiment cannot characterize chronic metabolic effects or uncommon harms. Appetite stimulation should be considered when evaluating claims about fat loss.
Source: Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Category 3 (nominated without enough support)
Listed in 503A category 3 ("GHRP-2", nominated without adequate support). Separately, FDA placed GHRP-2 (injectable and nasal) in 503B category 2 (significant safety risks) on September 29, 2023. source - World Anti-Doping Agency (2026)
- Prohibited, named on the list · S2.2.4 Growth hormone releasing factors
Named explicitly ("GHRP-2 (pralmorelin)"). source
FDA actions
- FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing GHRP-2 among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source
Other notes
- FDA lists GHRP-2 (injectable and nasal routes) in 503B category 2 for outsourcing facilities, citing immunogenicity and impurity risks. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & status
The selected human experiment measured short-term food intake. It does not establish a muscle-building, recovery, or weight-management treatment.
Source: Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Mechanism & research rationale
Activation of the growth-hormone secretagogue pathway can affect both endocrine signaling and appetite. A hormone change therefore does not fully describe its biological effects.
Source: Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. ↗
Molecular structure
Questions worth asking
- What specific product, route, and research population does the claim refer to?
- Does the source measure an outcome in people, or only a laboratory marker?
- Hormone-release measurements do not establish long-term muscle gain or a favorable benefit-risk balance.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Was food intake reduced in the cited experiment?
No. Participants ate more during active exposure.
Source: Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. ↗
Is a rise in growth hormone a muscle-gain result?
No. Muscle size, strength, function, and safety were not established by that endpoint.
Source: Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. ↗
References & editorial record
- FDA · Compounding safety concerns ↗
- PubMed · Animal comparator data · PMID 9849822 ↗
- Growth hormone releasing peptide-2 (GHRP-2), like ghrelin, increases food intake in healthy men. ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
